Skip to main content
Equibles
TDOC logo

TDOC · Teladoc Health, Inc. · Metrics

Track TDOC — free

Use TDOC with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$6.18 -0.08 (-1.28%)
Russell 2000 member Rebalance outlook locked
Customer concentration — key customers 31% of revenue

Key customers — 31% of revenue (the three months ended March 31, 2026)

“Revenue from the five largest Clients accounted for 31% of total Integrated Care segment revenue for each of the three months ended March 31, 2026 and 2025.”
View the 10-Q filed Apr 30, 2026
Market Cap
$1.14B
Shares
181.68M

TDOC metrics

70 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$6.26
Market cap
$1.14B

Price action

20 metrics
Price change (1W)
-3.4%
Price change (30D)
-11.3%
Price change (3M)
-10.9%
Price change (6M)
+23.6%
Price change (YTD)
-10.3%
Price change (1Y)
-17.7%
Trailing year
Price change (5Y)
-95.7%
52-week high
$9.72
52-week low
$4.47
Change from 52-week high
-35.4%
Change from 52-week low
+40.5%
Annualized volatility
63.9%
Annualized volatility (3M)
75.7%
Beta
1.3
RSI (14D)
38.8
Price vs SMA 50
-19.2%
Price vs SMA 200
-6.1%
Avg volume (3M)
4.61M
Relative volume
0.6
Average dollar volume
$35.40M

Company

3 metrics
Sector
Healthcare
Industry
Health Information Services
Shares outstanding
181.68M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.5×
reciprocal yield 218.2%
P / book
0.9
reciprocal yield 114.8%
FCF yield
22.2%
TTM · current market cap
Buyback yield
—
P / FCF
4.5
reciprocal yield 22.2%
P / operating cash flow
4.4
reciprocal yield 22.9%
Earnings yield
-15.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-07-29

Profitability

9 metrics
Gross margin
—
Operating margin
-7.5%
Trailing 12 months
Net margin
-7.1%
Gross profit (TTM)
$310.28M
Operating profit (TTM)
−$186.82M
Net income (TTM)
−$177.40M
Trailing 12 months
Diluted EPS (TTM)
$-0.99
FCF margin
10.2%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
$4.55
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-33.14

Growth

11 metrics
Revenue growth YoY
-4.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$2.49B
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2.9%
Year over year · more shares
Revenue CAGR (3Y)
+1.7%
Revenue CAGR (5Y)
+18.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
+18.2%
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-13.5%
Return on assets
-6.4%
Debt / equity
—
Current ratio
0.8
EBITDA (TTM)
−$3.71B
Free cash flow (TTM)
$253.70M
Quick ratio
0.8
Interest coverage
-9.4
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$774.35M
Total assets
$2.76B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$261.18M
Capital expenditures (TTM)
$7.49M
R&D (TTM)
$269.91M
SG&A (TTM)
—
Stock compensation (TTM)
$56.82M
R&D / revenue
10.8%
Stock compensation / revenue
2.3%

Ownership (13F)

3 metrics
13F filers
355
13F filer change QoQ
+22
Institutional ownership
89.5%

Short interest

3 metrics
Short interest
13.0%
Latest settlement · 5.0 days to cover
Days to cover
5.0d
Short-squeeze score
56 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$547,404
Insider-sentiment score
27 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1477449 CUSIP 87918A105 13F (30d) 206 filings 204 filers Visit website Investor relations